Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration.

Giannakaki-Zimmermann, Helena; Ebneter, Andreas; Munk, Marion; Wolf, Sebastian; Zinkernagel, Martin (2016). Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration. Ophthalmologica, 236(4), pp. 201-206. Karger 10.1159/000452929

Preview

Text 452929.pdf - Published Version Available under License Publisher holds Copyright. Download (219kB) | Preview

PURPOSE

To investigate outcomes in patients with neovascular age-related macular degeneration (AMD) switched from a pro re nata regimen (PRN) to a treat and extend regimen (TER) under aflibercept.

PROCEDURE

Thirty-two patients were observed over 2 years: the first year on PRN and the second year on TER. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were evaluated. Intra- and subretinal fluid as well as the number of visits and injections were assessed.

RESULTS

Both regimens resulted in a stable BCVA. Patients in TER had a significant decrease of CRT after 1 year compared to 1 year of treatment on PRN (p < 0.0001). TER resulted in significantly less visits; however, significantly more injections were observed over the course of 1 year compared to PRN (10.25 vs. 7.5, p < 0.0001 and 5.97 vs. 7.5, p = 0.0002, respectively).

CONCLUSION

A switch from PRN to TER in patients treated with aflibercept for AMD appears to be safe.

Interest & Impact

Downloads

321 since deposited on 09 Jan 2017
30 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item